All In Biotech

NDA 216540 · Bridgebio Pharma

Attruby

Acoramidis Hydrochloride · Oral

NovelOrphan

CDER novel approval, Nov 22, 2024: To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis

Last checked: Nov 19, 2026Latest source record: Nov 22, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Nov 22, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

12

6 Phase 3, 6 recruiting

FAERS reports

370

87 serious, 12 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 29, 2026.

ATTRUBY is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. ATTRUBY is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. ( 1 , 2.1 )

Mechanism: Acoramidis is a selective stabilizer of transthyretin (TTR). Acoramidis binds TTR at thyroxine binding sites and slows dissociation of the TTR tetramer into its constituent monomers, the rate-limiting step in amyloidogenesis.

Therapeutic areas: Cardiovascular and metabolic · Rare and genetic disease · Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 22, 2024 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
1 products under this application
  • ATTRUBY · ACORAMIDIS HYDROCHLORIDE EQ 356MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Acoramidis" as an intervention, any sponsor and status, largest first.

All 12 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea69
  • fatigue29
  • dizziness23
  • blood creatinine increased21
  • abdominal discomfort18
  • nausea18
  • dyspnoea16
  • weight decreased16
  • asthenia15
  • product dose omission issue15
  • abdominal pain upper13
  • rash11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2025189
2026181

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Attruby (Acoramidis HCl)

2024 spending

$870K

Beneficiaries

41

41 claims

Per beneficiary

$21,220

$165.28 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$870,032

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 16 on PubMed

Sponsor: Bridgebio Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.